(1 - 9 von 14
)
How Crescendo could earn $790m from Takeda deal - Cambridgeshire Live
www.cambridge-news.co.uk
Agreement will see life sciences firm's tech licensed
Crescendo Biologics Launches New Strategy in Oncology Drug Discovery...
lifesciences.instinctif.com
New focus launched alongside appointment of Dr Peter Pack as CEO Cambridge, UK – 14 October – Crescendo Biologics Limited (Crescendo), the drug ...
Takeda licenses Crescendo’s Humabodies - PharmaTimes
www.pharmatimes.com
Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets....
sortiert nach Relevanz / Datum